Onco Wiki / drapeau rouge

CML patient with positive HBV serology (HBsAg+ or anti-HBc+) — TKI therapy is associated...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-CML-INFECTION-SCREENING
TypeSignal d’alerte
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesDIS-CML
SourcesSRC-ELN-CML-2020 SRC-NCCN-MPN-2025

Origine du drapeau rouge

DéfinitionCML patient with positive HBV serology (HBsAg+ or anti-HBc+) — TKI therapy is associated with HBV reactivation in case reports; mandatory HBV testing pre-TKI + active prophylaxis (entecavir / tenofovir) if HBsAg+, monitoring if anti-HBc+ only
Direction cliniqueenquêter
Catégoriedépistage des infections

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "hbsag",
      "value": "positive"
    },
    {
      "finding": "anti_hbc_total",
      "value": "positive"
    },
    {
      "finding": "hcv_rna",
      "value": "positive"
    },
    {
      "finding": "hiv_status",
      "value": "positive"
    }
  ],
  "type": "composite"
}

Notes

Direction "investigate" — surfaces a workup-prerequisite annotation. CML TKI-related HBV reactivation is rare but reported (especially with immunosuppression-dose TKI shifts and post-TFR discontinuation). HBV testing recommended before initiating any TKI per ELN 2020 + NCCN. STUB — requires clinical co-lead signoff.

Utilisé par

Algorithmes

Indication